Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA May Ask Circulatory Panel To Revisit AF Burden Definition, CryoCor Says

This article was originally published in The Gray Sheet

Executive Summary

The CryoCor cardiac cryoablation system will be the first FDA-approved device for treating paroxysmal (episodic) atrial fibrillation by ablating the pulmonary vein ostia, the source of about one-third of all AF, according to San Diego developer CryoCor
Advertisement

Related Content

CardioFocus Illuminates Underserved “AF-Alone” Market With Light Ring
CardioFocus Illuminates Underserved “AF-Alone” Market With Light Ring
ADOPT-A Trial Kicks SJM Into Overdrive In Race For AF Suppression Pacing
ADOPT-A Trial Kicks SJM Into Overdrive In Race For AF Suppression Pacing
Advertisement
UsernamePublicRestriction

Register

MT016538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel